Champions Oncology, Inc.: Form 10-Q for the period ended Jul 31, 2022
Filed with the SEC on Sep 12, 2022 and accepted by EDGAR at Sep 12, 2022, 20:52 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-05-01 to 2022-07-31 | $13.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-05-01 to 2022-07-31 | $7.1m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2022-05-01 to 2022-07-31 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-05-01 to 2022-07-31 | −$284.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-05-01 to 2022-07-31 | $17.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-05-01 to 2022-07-31 | −$319.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-05-01 to 2022-07-31 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-05-01 to 2022-07-31 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-05-01 to 2022-07-31 | 13,522,433 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-05-01 to 2022-07-31 | −$195.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-05-01 to 2022-07-31 | $754.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-07-31 | $8.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-07-31 | $18.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-07-31 | $34.4m | us-gaap:Assets |
| Current liabilities | At period end2022-07-31 | $16.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-07-31 | $25.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-07-31 | $9.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-22-024751. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.